Abstract
Recent reports of clinical complications involving recombinant BMP-2 (rhBMP-2) have led to uncertainty in its current use. One possible explanation for the incidence of complications is the supraphysiologic dose required to achieve spine fusion. Improvements in carrier technology may allow surgeons to utilize rhBMP-2 by enhancing the local delivery of growth factors. The aim of this study was to investigate the spinal fusion capacity of a biodegradable nanofiber matrix containing a BMP-2-binding epitope.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have